Trader consensus on Polymarket prices an 87% chance against a new WHO-designated COVID-19 variant of concern (VOC) emerging before 2027, driven by widespread population immunity from repeated vaccinations and infections, alongside proactive genomic surveillance that catches mutations early. The recent BA.3.2 "Cicada" lineage, a highly mutated Omicron descendant detected in 23+ countries and 25-29 U.S. states since late 2025, has fueled media alerts for its potential immune escape but circulates at under 0.2% of sequences, shows no case surges, and remains sensitive to antivirals—falling short of VOC criteria like elevated transmissibility or severity. Global test positivity hovers at 3.4% with declining trends, underscoring COVID's endemic stability, though a rapid hospitalization spike could prompt reevaluation.